Lexicon Pharmaceuticals Inc [LXRX] fell -48.66% so far this year. What now?

MU Stock

Lexicon Pharmaceuticals Inc [NASDAQ: LXRX] closed the trading session at $13410000.0 on 2025-06-25. The day’s price range saw the stock hit a low of $0.7685, while the highest price level was $0.9153.

The stocks have a year to date performance of -48.66 percent and weekly performance of 24.69 percent. The stock has been moved at 24.17 percent over the last six months. The stock has performed 36.16 percent around the most recent 30 days and changed 151.61 percent over the most recent 3-months.

If compared to the average trading volume of 13.41M shares, LXRX reached to a volume of 11341997 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Lexicon Pharmaceuticals Inc [LXRX]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for LXRX shares is $2.92 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on LXRX stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Leerink Partners have made an estimate for Lexicon Pharmaceuticals Inc shares, keeping their opinion on the stock as Market Perform, with their previous recommendation back on March 05, 2025. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on June 17, 2024, representing the official price target for Lexicon Pharmaceuticals Inc stock. Previously, the target price had yet another raise to $5, while Leerink Partners analysts kept a Outperform rating on LXRX stock.

The Price to Book ratio for the last quarter was 2.65, with the Price to Cash per share for the same quarter was set at 0.54.

LXRX stock trade performance evaluation

Lexicon Pharmaceuticals Inc [LXRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 24.69. With this latest performance, LXRX shares gained by 36.16% in over the last four-week period, additionally plugging by 24.17% over the last 6 months – not to mention a rise of 21.67% in the past year of trading.

Lexicon Pharmaceuticals Inc [LXRX]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Lexicon Pharmaceuticals Inc [LXRX] shares currently have an operating margin of -540.04% and a Gross Margin at 96.22%. Lexicon Pharmaceuticals Inc’s Net Margin is presently recorded at -568.04%.

Return on Equity for this stock declined to -49.60%, with Return on Assets sitting at -49.60%.

Earnings per share (EPS) analysis for Lexicon Pharmaceuticals Inc [LXRX] stock

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for LXRX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Lexicon Pharmaceuticals Inc go to 30.30%.

Lexicon Pharmaceuticals Inc [LXRX]: Institutional Ownership

There are presently around $74.93%, or 75.82% of LXRX stock, in the hands of institutional investors. The top three institutional holders of LXRX stocks are: ARTAL GROUP S.A. with ownership of 175.1 million shares, which is approximately 56.3318%. FMR LLC, holding 38.69 million shares of the stock with an approximate value of $$64.99 million in LXRX stocks shares; and FMR LLC, currently with $$16.62 million in LXRX stock with ownership which is approximately 3.1818%.

The DBT News
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.